CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

Palbociclib, ribociclib, and abemaciclib belong to the third generation of cyclin-dependent kinases inhibitors (CDKis), an established therapeutic class for advanced and metastatic breast cancer. Interindividual variability in the therapeutic response of CDKis has been reported and some individuals...

Full description

Bibliographic Details
Main Authors: Rossana Roncato, Jacopo Angelini, Arianna Pani, Erika Cecchin, Andrea Sartore-Bianchi, Salvatore Siena, Elena De De Mattia, Francesco Scaglione, Giuseppe Toffoli
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:International Journal of Molecular Sciences
Subjects:
cyclin-dependent kinases inhibitors
breast cancer
personalized medicine
Online Access:https://www.mdpi.com/1422-0067/21/17/6350

Internet

https://www.mdpi.com/1422-0067/21/17/6350

Similar Items